Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:10/1/2014)...   Royal Philips (NYSE: ... and eCareCompanion telehealth applications have received 510(k) clearance ... A part of Philips Hospital to Home,s ... are focused on patient care within the home ... available through the cloud-based digital health platform, which ...
(Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
(Date:9/30/2014)... 30, 2014  Wrightington, Wigan ... MDRX ) are delighted to announce WWL,s ... new health information system. The system will be implemented ... the way WWL delivers healthcare in the future. ... record of on-time and on-budget system implementations as well ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
... July 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... Proxy Advisory Services,("ISS"), a leading independent proxy voting and corporate ... River,s proposed,acquisition of WuXi. Two other proxy advisory services, Glass ... the,transaction. , , ...
Cached Medicine Technology:HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining how ... , Smoking will always have a negative impact on ... method to find affordable coverage. Insurance brokerage websites specialize ... , Whole life insurance premiums will be fixed throughout ... is permanent, the initial rates are very important. ...
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... Diet Doc understands that many of their clients ... their dieting attempts could be easily sabotaged by the temptation ... treatments into their programs as a way to control ... effective weight loss results, it also allows patients to stick ... their weight for the future. , Earlier versions of the ...
(Date:10/1/2014)... the occasion of the Leishmaniasis East Africa Platform ... international leishmaniasis experts, results of a pharmacovigilance ... plan, carried out by MSF, DNDi, and national ... presented to key decision makers in order to ... the combination of Sodium Stibogluconate and Paromomycin (SSG&PM) ...
(Date:10/1/2014)... Today marks the final day prosthodontist Dr. Saj ... and Woodland Hills, Calif., is in the southern India ... “Speaking to this group of specialists allows more people ... help and care they deserve,” Dr. Jivraj said. , ... providing cosmetic dentistry, correcting bite issues, placing implants, and ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... 27 New Jersey Senate Majority Leader Stephen M. Sweeney ... join Labor Leaders Charles Wowkanech , President of the New ... Counties Central Labor Council and Henry Nichola s, President of ... rallies in Deptford and Hammonton, N. J., in support of ...
... Governor Edward G. Rendell today announced that ... Senate confirmation:State Board of Medicine , James W. ... of Nursing Home Administrators , Mary Ann Hewston, ... creating a first-rate public education system, protecting our ...
... Healthier, More Productive PracticeNEWBERG, Ore., Feb. 27 ... is well-positioned to fit small spaces and conservative ... a mid-level platform choice that,s lower in cost ... performance, service, and support that distinguish A-dec products. ...
... can be used on all women with diagnosis, study ... new genetic test that analyzes a set of 50 ... lead to quicker, more immediate treatment for patients, according ... "Unlike a widely used genomic test that applies only ...
... Refute USA Today ReportHARRISBURG, Pa., Feb. 27 The ... unsafe levels of air pollutants or metals after extensively ... schools.Environmental Protection acting Secretary John Hanger said that the ... USA Today in December 2008 that relied only ...
... Feb. 27 Smith & Nephew, Inc.,(NYSE: ... announced the,introduction of a metal liner option for its ... in hip replacement and resurfacing,procedures. , ... Food and Drug Administration,for use with the BIRMINGHAM HIP(TM) ...
Cached Medicine News:Health News:Politicians and Labor Leaders Set to Lead Rallies Saturday (February 28) for Striking Innova Nurses 2Health News:New A-dec 300(TM) Offers Dentists an Innovative Equipment Solution 2Health News:New Test May Mean Faster Breast Cancer Treatment 2Health News:PA DEP Finds Air Quality Around Schools to be Safe 2Health News:PA DEP Finds Air Quality Around Schools to be Safe 3Health News:Smith & Nephew Introduces Metal Liner Option for the Modular R3(TM) Acetabular Cup System 2Health News:Smith & Nephew Introduces Metal Liner Option for the Modular R3(TM) Acetabular Cup System 3
... secreted by the kidney, plays a ... The renin-angiotensin system regulates blood pressure, ... by the kidney. Renin is secreted ... decreased intravascular volume and decreased plasma ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... also known as bone Gla protein, is ... is a major component of the noncollagenous ... osteoblasts in bone, with a small amount ... chondrocytes [1]. During bone formation, newly synthesized ...
Medicine Products: